


Product Details

Product name:	Anti-Ang2 & VEGFA (Vanucizumab Biosimilar)	SKU:	BIO0940SM
Target Name:	Ang2 & VEGFA	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	Q9UID3 & P15692	Concentration:	Lyophilized
Clone#:	Vanucizumab (Bispecific)	Isotype:	IgG-like
Reactivity:	Human	Calculated M.W.:	146.89 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 96%.

Purity: SEC-HPLC




The purity of Anti-ANG2 & VEGFA Reference Antibody (Vanucizumab) is more than 95%, determined by SEC-HPLC.

Bioactivity: ELISA




Vanucizumab bound to ANG2 protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Vanucizumab bound to in huANG2-His, and the EC₅₀ was 0.288 nM.

ELISA



Vanucizumab bound to VEGFA protein, and then rebounded to secondary antibodies (Anti-Human-IgG-Fc-HRP), and read OD450. As shown in fig, Vanucizumab bound to in huVEGFA-His, and the EC₅₀ was 0.009 nM.

Function: Luciferase



Co-incubation of Vanucizumab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vanucizumab can neutralize VEGF-165, and the IC50 was 1.075 nM.